Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 12/20 | 0.46 |
| ▸ | AKT2 | P31751 | 11/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22673510 | 1.00 | AKT1 (0.46) | AKT1AKT2NPC1RAB9AL3MBTL1 | |
| SCHEMBL22673323 | 0.98 | AKT1 (0.43) | AKT1AKT2NPC1RAB9AL3MBTL1 | |
| SCHEMBL22673682 | 0.98 | AKT1 (0.43) | AKT1AKT2NPC1RAB9AL3MBTL1 | |
| SCHEMBL22673680 | 0.97 | AKT1 (0.44) | AKT1AKT2NPC1RAB9AL3MBTL1 | |
| SCHEMBL25789245 | 0.96 | AKT1 (0.43) | AKT1AKT2NPC1RAB9AL3MBTL1 | |
| SCHEMBL22673528 | 0.94 | AKT1 (0.48) | AKT1AKT2NPC1RAB9AL3MBTL1 | |
| SCHEMBL22674196 | 0.94 | AKT1 (0.48) | AKT1AKT2NPC1RAB9AL3MBTL1 | |
| SCHEMBL22673504 | 0.93 | AKT1 (0.47) | AKT1AKT2NPC1RAB9AL3MBTL1 | |
| SCHEMBL24479248 | 0.93 | AKT1 (0.47) | AKT1AKT2NPC1RAB9AL3MBTL1 | |
| SCHEMBL25789300 | 0.93 | AKT1 (0.39) | AKT1AKT2NPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169661-A1 | IMIDAZO NITROGEN HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | GUANGDONG AGLAIA OPTOELECTRONIC MATERIALS CO., LTD (CN) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169661-A1 | IMIDAZO NITROGEN HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | HCN4, IPO8, HCN1 | AKT1 2630/4885AKT2 2749/4885NPC1 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.